TrialCancer immunology, immunotherapy : CII2023

A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.

Nathaniel Dasyam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.